Trial · NCT04782115
Evaluation of RC28-E Injection in Diabetic Macular Edema
NCT04782115, Phase 2, Completed, RemeGen Co., Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Evaluation of RC28-E Injection in Diabetic Macular Edema. Trials, record NCT04782115. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04782115
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of RC28-E Injection in Diabetic Macular Edema
- NCT number
- NCT04782115
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 156 participants, actual
- Lead sponsor
- RemeGen Co., Ltd.
- Conditions
- Diabetic Macular Edema
- Interventions
- intravitreal injection of RC28-E, Conbercept
- First posted
- 2021-03-04
- Last updated
- 2023-12-18
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change from baseline in BCVA at 24 week; | Baseline,week 24 | BCVA=Best-corrected visual acuity;Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts. |
| Primary | Mean change from baseline in BCVA at 52 week; | Baseline, Week 52 | Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts. |
| Secondary | Mean change from baseline in BCVA at every visit during treatment period; | Baseline up to Week 52 | Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts. |
| Secondary | Mean change from baseline in central subfield thickness at 12, 24, 36, 52 week. | 12, 24, 36, 52 week. | Measurement of central subfield thickness by OCT. |
| Secondary | Percentage of subjects with VA improvement (who gained >0 letters, ≥5 letters, ≥10 letters, ≥ 15 letters in their BCVA) from baseline at 52 week; | Baseline up to Week 52 | Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts. |
| Secondary | Percentage of subjects with VA worsen (who lost ≥5 letters, ≥10 letters, ≥15 letters in their BCVA) from baseline at 52 week; | Baseline, Week 52 | Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts. |
| Secondary | Percentage of subjects with BCVA ≥ 68 letters(a visual acuity Snellen equivalent of 20/40 or better) at 52 week; | Baseline, Week 52 | Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts. |
| Secondary | Frequency of administration RC28-E; | Baseline, Week 52 | Number of intravitreal injections |
| Secondary | Safety of RC28-E injection | Baseline up to Week 52 | Incidence of AE in ocular and non-ocular |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40122579 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04782115
GET https://conductscience.org/api/trials/v1/NCT04782115/registered